首页|凉血解毒利湿方联合血浆置换对乙肝相关慢加急性肝衰竭患者预后的临床观察

凉血解毒利湿方联合血浆置换对乙肝相关慢加急性肝衰竭患者预后的临床观察

扫码查看
目的 观察凉血解毒利湿方联合血浆置换对乙肝相关慢加急性肝衰竭(HBV-ACLF)患者预后的影响.方法 76例HBV-ACLF患者按随机数字表法分为对照组与观察组各38例.对照组予以血浆置换治疗,观察组在对照组的基础上联合凉血解毒利湿方.治疗3周后,对比两组治疗前后中医证候积分、肝功能[白蛋白(ALB)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、总胆红素(TBil)]、炎性因子[肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、白细胞介素-10(IL-10)]、T淋巴细胞亚群水平,并对治疗的有效率、安全性以及患者预后情况进行评价.结果 治疗后,两组患者的中医证候积分均降低,且观察组身目俱黄、高热烦渴、舌红苔黄、小便色黄、倦怠乏力等积分低于对照组(P<0.05);治疗后,两组患者的ALB、IL-10、CD4+、CD4+/CD8+均升高,ALT、AST、TBil、TNF-α、IL-6、CD8+均下降(P<0.05),且观察组上述指标的改善幅度大于对照组(P<0.05);观察组治疗总有效率为92.11%,高于对照组的73.68%(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05).结论 凉血解毒利湿方联合血浆置换治疗HBV-ACLF效果较好,能明显缓解患者的临床症状,调节其肝功能与免疫功能状态,抑制炎症反应,促进预后,较为安全.
Effect of Liangxue Jiedu Lishui Decoction Combined with Plasma Exchange on Prognosis of Patients with Hepatitis B Related Chronic Acute Liver Failure
Objective:To investigate the effect of Liangxue Jiedu Lishi Decoction combined with plasma ex-change on the prognosis of patients with hepatitis B-related chronic acute liver failure(HBV-ACLF).Methods:A total of 76 patients with HBV-ACLF were divided into the control group and observation group with 38 patients respectively according to random number table method.The control group was treated with plasma exchange,and the observation group was combined with the prescription of Liangxue Jiedu Lishi Decoction on the basis of the con-trol group.Three weeks after treatment,TCM syndrome scores,liver function[albumin(ALB),glutamic-pyruginase(ALT),glutamic-oxalic aminotransferase(AST),total bilirubin(TBil)],inflammatory factors[tumor necrosis factor(TNF-α),interleukin-6(IL-6),interleukin-10(IL-10)]and T lymphocyte subsets before and after treatment were compared between the two groups.The efficacy,safety and prognosis of the patients were evaluated.Results:After treatment,the TCM syndrome scores of both groups were decreased,and the scores of jaundice,high fever with thirst,red tongue with yellow coating,yellowish urine,and fatigue in the observation group were lower than those of the control group(P<0.05).After treatment,ALB,IL-10,CD4+,CD4+/CD8+were increased in both groups,while ALT,AST,TBil,TNF-α,IL-6 and CD8+were decreased(P<0.05),and the improvement of these in-dexes in observation group was greater than that in control group(P<0.05).The total effective rate of observation group was 92.11%,which was higher than 73.68%of control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The treatment of HBV-ACLF with Liangxue Jiedu Lishi Decoction combined with plasma therapy is effective,can significantly relieve the clinical symptoms of patients,regulate the liver function and immune function,inhibit the inflammatory response,promote the prognosis,and is relatively safe.

Hepatitis B-related chronic plus acute liver failureSyndrome of blazing heat-toxinLiangxue Jiedu Lishi DecoctionPlasma exchangeInflammatory factorsT lymphocytesprognosis

肖海鹏、吴安定、黄昱

展开 >

湖北省黄冈市中心医院,湖北黄冈 438000

乙肝相关慢加急性肝衰竭 热毒炽盛证 凉血解毒利湿方 血浆置换 炎性因子 T淋巴细胞 预后

湖北省健康委员会科研项目

WJ2021M083

2024

中国中医急症
中华中医药学会

中国中医急症

CSTPCD
影响因子:1.144
ISSN:1004-745X
年,卷(期):2024.33(6)
  • 22